185 related articles for article (PubMed ID: 17587642)
1. Cutaneous silent period in patients with restless leg syndrome.
Han JK; Oh K; Kim BJ; Koh SB; Kim JY; Park KW; Lee DH
Clin Neurophysiol; 2007 Aug; 118(8):1705-10. PubMed ID: 17587642
[TBL] [Abstract][Full Text] [Related]
2. Effect of pramipexole on cutaneous-silent-period parameters in patients with restless legs syndrome.
Öz O; Erdoğan Ç; Yücel M; Akgün H; Kütükçü Y; Gökçil Z; Odabaşi Z
Clin Neurophysiol; 2012 Jan; 123(1):154-9. PubMed ID: 21757401
[TBL] [Abstract][Full Text] [Related]
3. Influence of cabergoline on motor excitability in patients with restless legs syndrome.
Gorsler A; Liepert J
J Clin Neurophysiol; 2007 Dec; 24(6):456-60. PubMed ID: 18090527
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous silent period changes in Type 2 diabetes mellitus patients with small fiber neuropathy.
Onal MR; Ulas UH; Oz O; Bek VS; Yucel M; Taslipinar A; Odabasi Z
Clin Neurophysiol; 2010 May; 121(5):714-8. PubMed ID: 20138004
[TBL] [Abstract][Full Text] [Related]
5. Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients.
Hornyak M; Hundemer HP; Quail D; Riemann D; Voderholzer U; Trenkwalder C
Clin Neurophysiol; 2007 Jul; 118(7):1532-7. PubMed ID: 17531532
[TBL] [Abstract][Full Text] [Related]
6. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome.
García-Borreguero D; Kohnen R; Högl B; Ferini-Strambi L; Hadjigeorgiou GM; Hornyak M; de Weerd AW; Happe S; Stiasny-Kolster K; Gschliesser V; Egatz R; Cabrero B; Frauscher B; Trenkwalder C; Hening WA; Allen RP
Sleep Med; 2007 Aug; 8(5):455-63. PubMed ID: 17543579
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.
Giorgi L; Ritchie SY; Kirsch JM
Curr Med Res Opin; 2006 Oct; 22(10):1867-77. PubMed ID: 17022844
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset.
Allen RP; Ritchie SY
Sleep Med; 2008 Dec; 9(8):899-902. PubMed ID: 18024167
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease.
Nomura T; Inoue Y; Nakashima K
J Neurol Sci; 2006 Dec; 250(1-2):39-44. PubMed ID: 16899256
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone response to low-dose apomorphine in restless legs syndrome.
Happe S; Bachmann CG; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Growth Horm IGF Res; 2007 Aug; 17(4):323-7. PubMed ID: 17512770
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of periodic leg movements and associated transcranial magnetic stimulation parameters in restless legs syndrome.
Kutukcu Y; Dogruer E; Yetkin S; Ozgen F; Vural O; Aydin H
Muscle Nerve; 2006 Jan; 33(1):133-7. PubMed ID: 16175624
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous silent periods of the vastus medialis evoked by the stimulation of lateral femoral cutaneous nerve.
Tataroglu C; Uludag B; Karapinar N; Bademkiran F; Ertekin C
Clin Neurophysiol; 2005 Jun; 116(6):1335-41. PubMed ID: 15978495
[TBL] [Abstract][Full Text] [Related]
14. Enhanced external counter pulsation (EECP) as a novel treatment for restless legs syndrome (RLS): a preliminary test of the vascular neurologic hypothesis for RLS.
Rajaram SS; Shanahan J; Ash C; Walters AS; Weisfogel G
Sleep Med; 2005 Mar; 6(2):101-6. PubMed ID: 15716213
[TBL] [Abstract][Full Text] [Related]
15. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
16. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
17. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
Frauscher B; Gschliesser V; Brandauer E; El-Demerdash E; Kaneider M; Rücker L; Poewe W; Högl B
Sleep Med; 2009 Jun; 10(6):611-5. PubMed ID: 19200780
[TBL] [Abstract][Full Text] [Related]
18. Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation?
Paulus W; Schomburg ED
Sleep Med Rev; 2006 Jun; 10(3):185-96. PubMed ID: 16762808
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of restless legs syndrome with dopamine agonists.
Ondo W; Romanyshyn J; Vuong KD; Lai D
Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
[TBL] [Abstract][Full Text] [Related]
20. Excessive Daytime sleepiness in idiopathic restless legs syndrome: characteristics and evolution under dopaminergic treatment.
Kallweit U; Siccoli MM; Poryazova R; Werth E; Bassetti CL
Eur Neurol; 2009; 62(3):176-9. PubMed ID: 19602890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
